Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
2.710
-0.130 (-4.58%)
At close: Aug 28, 2025, 4:00 PM
2.710
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:10 PM EDT
Orchestra BioMed Holdings Stock Forecast
OBIO's stock price has decreased by -57.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Orchestra BioMed Holdings stock have a consensus rating of "Strong Buy" and an average price target of $14.67, which forecasts a 441.33% increase in the stock price over the next year. The lowest target is $12 and the highest is $20.
Price Target: $14.67 (+441.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +638.01% | Aug 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +638.01% | Aug 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +638.01% | May 13, 2025 |
| Barclays | Barclays | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +342.80% | May 5, 2025 |
Financial Forecast
Revenue This Year
3.16M
from 2.64M
Increased by 19.83%
Revenue Next Year
3.56M
from 3.16M
Increased by 12.53%
EPS This Year
-1.98
from -1.66
EPS Next Year
-1.67
from -1.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.2M | 5.3M | |||
| Avg | 3.2M | 3.6M | |||
| Low | 1.7M | 1.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.2% | 66.1% | |||
| Avg | 19.8% | 12.5% | |||
| Low | -36.5% | -65.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.86 | -1.51 | |||
| Avg | -1.98 | -1.67 | |||
| Low | -2.03 | -1.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.